With so many multi-trillion dollar ideas floating around Washington, it is easy to forget that some of them are going to produce meaningful results over time. The relief bills that passed in 2020 dedicated enormous resources to scientific research in biotechnology, among other things.
The possibilities are endless for genetics, therapeutics, testing and vaccines. In the near term, it means medically/scientifically trained people are in high demand across the whole spectrum of health care, research and drug development. There is also going to be continued high demand for the raw materials of research; hardware, consumables and other supplies. Perhaps this sector is not the best place to look for the post-COVID roll-over trade. ;-)
Have a great day.
Emily Evans
Managing Director – Health Policy
Twitter
LinkedIn
